BIOKANGTAI Overview

  • Founded
  • 1992

Founded
  • Status
  • Public

  • Employees
  • 2,445

Employees
  • Stock Symbol
  • 300601

Stock Symbol
  • Share Price
  • $5.52

  • (As of Friday Closing)

BIOKANGTAI General Information

Description

Shenzhen Kangtai Biological Products Co Ltd is a human vaccine research and development company. The company is engaged in the research and development, production and sales of recombinant hepatitis B vaccine, b -type influenza Haemophilus conjugate vaccine, measles-rubella combined live attenuated vaccine, cell-free baibai broke b Haemophilus influenzae vaccine and other products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
SHE
Primary Office
  • No.18,Shutianpu Road
  • Guangming District
  • Shenzhen, Guangdong 518107
  • China
+86 0755 0000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BIOKANGTAI Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.52 $5.62 $3.76 - $9.40 $6.19B 1.12B 12.9M -$0.02

BIOKANGTAI Financials Summary

In Thousands,
USD
TTM 30-Sep-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 4,727,212 10,350,430 18,113,118 8,111,072
Revenue 585,821 565,595 327,298 281,249
EBITDA 66,297 276,217 122,111 108,810
Net Income 65,649 195,658 98,310 83,146
Total Assets 1,945,059 2,219,762 1,467,024 564,888
Total Debt 322,840 429,567 13,957 36,591
Public Fundamental Data provided by Morningstar, Inc. disclaimer

BIOKANGTAI Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore BIOKANGTAI‘s full profile, request access.

Request a free trial

BIOKANGTAI Patents

BIOKANGTAI Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021105902-A4 Tetravalent influenza virus chicken embryo culture processes, tetravalent influenza virus split vaccines and preparation methods thereof Active 19-Aug-2021 00000000
AU-2021107276-A4 Purification process of chicken embryo allantoic fluid of tetravalent influenza virus, tetravalent influenza virus split vaccine and preparation method thereof Active 29-Dec-2020 000000000

BIOKANGTAI Executive Team (2)

Name Title Board Seat Contact Info
Weimin Du Chairman & Board Member
Haifa Zheng Board Member & Vice Chairman
To view BIOKANGTAI’s complete executive team members history, request access »

BIOKANGTAI Board Members (2)

Name Representing Role Since
Haifa Zheng BIOKANGTAI Board Member & Vice Chairman 000 0000
Weimin Du BIOKANGTAI Chairman & Board Member 000 0000
To view BIOKANGTAI’s complete board members history, request access »

BIOKANGTAI Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BIOKANGTAI Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore BIOKANGTAI‘s full profile, request access.

Request a free trial

BIOKANGTAI ESG

Risk Overview

Risk Rating

Updated May, 06, 2022

30.55 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,613

Rank

00.0

Percentile

Pharmaceuticals

Industry

00 of 1,004

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 462

Rank

00.00

Percentile

To view BIOKANGTAI’s complete esg history, request access »